Evaluation of In Vitro Activity of Ceftolozane/Tazobactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Pseudomonas aeruginosa Strains and Mechanisms of Carbapenem Resistance: Data from Tertiary Care Hospital

被引:2
|
作者
Hazirolan, Gulsen [1 ]
Ozkul, Ceren [2 ]
机构
[1] Hacettepe Univ, Dept Med Microbiol, Med Fac, Ankara, Turkiye
[2] Hacettepe Univ, Dept Pharmaceut Microbiol, Fac Pharm, Ankara, Turkiye
关键词
Carbapenems; Efflux Pumps; Pa beta N; Pseudomonas aeruginosa; Ceftolozane/Tazobactam; Ceftazidime/Avibactam; METALLO-BETA-LACTAMASE; MULTIPLEX PCR; EFFLUX PUMP; 1ST REPORT; AVIBACTAM; TAZOBACTAM; PREVALENCE; EXPRESSION; EMERGENCE;
D O I
10.5812/jjm-134090
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Carbapenem-resistant Pseudomonas aeruginosa is an endemic problem in several countries, notably Turkey. Objectives: This study aimed to investigate the underlying mechanisms contributing to the carbapenem resistance phenotype and enhance the in-vitro activity of ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (C/A) against carbapenem-resistant P. aeruginosa strains. Methods: A total of 114 carbapenem-resistant P. aeruginosa strains were isolated from different types of clinical specimens. The tested antibiotics were evaluated using the antibiotic disk diffusion method. Additionally, C/TandC/A were tested using the gradient test method. The efficacy of phenylalanine-arginine-beta-naphthylamide (PA beta N) as efflux pump inhibitors was assessed to determine their ability to reduce meropenem minimum inhibitory concentrations. Polymerase chain reaction (PCR) assays were conducted to identify bla(IMP), bla(VIM), and bla(NDM-1). Results: Among114 strains of carbapenem-resistant P. aeruginosa, overall resistance rates for C/T and C/A were 10.7% and 8.8%, respectively. Efflux pump inhibitor-based antibiotic susceptibility testing indicated that 35.08% of strains showed resistance modulated by PA beta N. Among the strains, 27 (24.5%) were found to produce metallo-beta-lactamase (MBL), with bla(VIM) (17 strains, 14.91%) being the most common, followed by bla(IMP) (12 strains, 10.53%). Conclusions: Emerging carbapenem resistance in P. aeruginosa strains is a serious therapeutic challenge for clinicians. Carbapenem resistance can be influenced by various factors, some of which were not assessed in our study. Nonetheless, our results revealed that themainmechanismassociated with carbapenem-resistant P. aeruginosa strains is a PA beta N-sensitiveeffluxpump. Among acquired MBLs, VIM-type enzymes were found to be the most prevalent.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Coexistence of multidrug resistance mechanisms and virulence genes in carbapenem-resistant Pseudomonas aeruginosa strains from a tertiary care hospital in South India
    Ellappan, Kalaiarasan
    Narasimha, Harish Belgode
    Kumar, Saravana
    [J]. JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2018, 12 : 37 - 43
  • [22] Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021
    Lee, Yu-Lin
    Hsueh, Po-Ren
    [J]. JOURNAL OF INFECTION, 2023, 87 (01) : E1 - E4
  • [23] Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany
    Kresken, Michael
    Koerber-Irrgang, Barbara
    Korte-Berwanger, Miriam
    Pfennigwerth, Niels
    Gatermann, Soeren G.
    Seifert, Harald
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (06)
  • [24] Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection
    Chen, Juan
    Liang, Qiqiang
    Chen, Xinyi
    Wu, Jing
    Wu, Yanchao
    Teng, Gaoqin
    Huang, Man
    [J]. INFECTION AND DRUG RESISTANCE, 2022, 15 : 655 - 667
  • [25] In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
    Malisova, Lucia
    Vrbova, Iveta
    Pomorska, Katarina
    Jakubu, Vladislav
    Zemlickova, Helena
    [J]. MICROBIAL DRUG RESISTANCE, 2023, 29 (10) : 485 - 491
  • [26] Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients
    Chen, Juan
    Liang, Qiqiang
    Ding, Shuo
    Xu, Yongshan
    Hu, Yanting
    Chen, Jingyu
    Huang, Man
    [J]. INFECTION AND DRUG RESISTANCE, 2023, 16 : 2237 - 2246
  • [27] Molecular Analysis of Carbapenem and Aminoglycoside Resistance Genes in Carbapenem-Resistant Pseudomonas aeruginosa Clinical Strains: A Challenge for Tertiary Care Hospitals
    Gondal, Aamir Jamal
    Choudhry, Nakhshab
    Niaz, Ammara
    Yasmin, Nighat
    [J]. ANTIBIOTICS-BASEL, 2024, 13 (02):
  • [28] Comparative in vitro bactericidal activity between cefepime and ceftazidime, alone and associated with amikacin, against carbapenem-resistant Pseudomonas aeruginosa strains
    Bantar, C
    Di Chiara, M
    Nicola, F
    Relloso, S
    Smayevsky, J
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 37 (01) : 41 - 44
  • [29] Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales
    Bail, Larissa
    Sanches Ito, Carmen Antonia
    Villa Stangler Arend, Lavinia Nery
    Nogueira, Keite da Silva
    Tuon, Felipe Francisco
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2022, 102 (01)
  • [30] Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa
    Nasomsong, Worapong
    Nulsopapon, Parnrada
    Changpradub, Dhitiwat
    Pungcharoenkijkul, Supanun
    Hanyanunt, Patomroek
    Chatreewattanakul, Tassanawan
    Santimaleeworagun, Wichai
    [J]. ANTIBIOTICS-BASEL, 2022, 11 (04):